CERKL

The CERKL gene provides instructions for a protein that contains regions resembling an enzyme called ceramide kinase. Despite that name, the protein does not actually add a phosphate to ceramide, and the molecule it truly acts on is still unknown. Researchers think the protein may help protect photoreceptors — the light-sensing cells of the retina — from stress and from a form of programmed cell death called apoptosis. The gene was first identified at a genetic location historically called RP26, an early name still seen in some records. Because CERKL-related disease is inherited recessively, it typically appears only when both inherited copies of the gene carry disease-causing changes.

In the largest study to date, which followed 47 people from 37 families, the most common first symptom was loss of central, straight-ahead vision. Well-demarcated patches of macular atrophy — thinning of the central retina — were the most frequently observed feature. Testing of retinal function showed a range of patterns, with rods and cones often affected to a similar degree, while some people had a rod-predominant, cone-predominant, or mainly macular pattern. An unusual and distinctive feature reported in some people is early macular change with relatively preserved sharpness of vision at first, followed by later central decline. Worsening night blindness over a few years has also been described. Over the first five years of follow-up in the large cohort, more than half of participants lost a meaningful amount of visual acuity in at least one eye.

CERKL is a well-established cause of autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) retinal degeneration and appears repeatedly across inherited retinal disease cohorts worldwide. It has been reported in patients from many populations, including studies in Tunisia, India, Pakistan, Jordan, China, the United Arab Emirates and Turkey. In some communities, a single shared "founder" variant accounts for many cases, such as a recurrent deletion reported in a North Indian ethnic group. The natural history study (definition: A study that follows people with a condition over time without giving a new treatment, to understand how the condition normally progresses.) found that people carrying two variants expected to eliminate the protein entirely — a "double-null" pattern — tended to have earlier onset and more severe degeneration. Imaging features such as outer retinal tubulation and peripheral chorioretinal atrophy have been documented in some people with CERKL variants.

The precise job of the CERKL protein in the retina is still being worked out, and its natural target has not been identified. Because the range of presentations is so broad — from isolated macular disease to widespread retinal involvement — it is difficult to predict how any one person's vision will change over time. The disease has been labeled both retinitis pigmentosa and cone-rod dystrophy, and some researchers argue that certain families fit cone-rod dystrophy better than the originally assigned diagnosis. Much of the current understanding of how CERKL loss damages the retina comes from animal and cell studies, which may not translate directly to people.

Research into how CERKL causes retinal degeneration is active but remains at the laboratory and animal stage. In mice missing most CERKL function, retinas show progressive photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) loss and problems clearing spent photoreceptor material. Other studies point to roles for CERKL in handling oxidative stress and in mitochondrial function within retinal cells. One recent study in zebrafish and cultured cells suggested that supplementing a lipid called phosphatidylcholine reduced fatty-droplet buildup and helped preserve photoreceptor structure. That result is an early, experimental finding and has not been tested as a treatment in people, so it should not be taken as a recommended therapy.

• A mouse model that mimics human CERKL disease

  Animal (laboratory) research.

  What was found:

  The mice showed progressive photoreceptor loss, fewer cones, poorly formed photoreceptor structures, and defective clearing of photoreceptor material by the supporting retinal layer.

  Why it matters:

  It provides a laboratory model that resembles the human disease and can be used to test future treatments.

  Limitation: Findings in mice do not always translate to humans and do not represent an available therapy.

• A possible mechanism involving photoreceptor waste clearance

  Animal and cell (laboratory) research.

  What was found:

  The fish developed rod-predominant photoreceptor degeneration with buildup of shed outer segments, linked to reduced levels of a phagocytosis protein called MERTK.

  Why it matters:

  It suggests one way loss of CERKL may harm the retina, by impairing removal of worn-out photoreceptor material.

  Limitation: Zebrafish and cell findings may differ from human biology, and the study is mechanistic rather than a treatment.

• An early, experimental idea for a metabolic therapy

  Animal and cell (laboratory) research.

  What was found:

  Loss of CERKL caused fatty-droplet buildup and low phosphatidylcholine levels, and supplementing phosphatidylcholine reduced the buildup and helped preserve photoreceptor structure.

  Why it matters:

  It points to a possible metabolism-based approach that researchers hope to explore further.

  Limitation: This has not been tested in people and is not an approved or available treatment.

• The largest look at how CERKL disease presents and progresses

  Observational human cohort (natural history).

  What was found:

  Central vision loss was the most common first symptom, macular atrophy was the most common feature, and retinal function fell across a broad range rather than a single pattern; people with "double-null" genotypes tended to have earlier and more severe disease.

  Why it matters:

  It gives patients and clinicians the clearest available picture of the wide variability and general course of CERKL-related retinal disease.

  Limitation: It was retrospective and drawn from two specialist centers, so it may not capture milder or undiagnosed cases.

• An unusual early presentation that can point to CERKL

  Case series (small human report).

  What was found:

  Both had early macular atrophy yet relatively preserved sharpness of vision at first, with non-recordable electroretinography and thinning of the central retina; central vision declined later.

  Why it matters:

  Recognizing this distinctive early pattern can prompt earlier genetic diagnosis and counseling.

  Limitation: Only two patients were described, so the findings cannot be generalized to everyone with CERKL variants.

Because CERKL-related disease is inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) pattern, biological siblings may carry the same combination of variants even before symptoms appear, which families may wish to discuss with a genetic counselor. Symptoms have been reported beginning in childhood in some people, which can matter for schooling and early support planning. The CERKL-related disease described in the reviewed evidence is limited to the eye and is not reported alongside hearing, kidney, or other whole-body problems. Otherwise, the general caregiver and accessibility guidance shown on every gene page applies here.

• Does my genetic result show two disease-causing CERKL variants, and are they thought to remove the protein entirely?
• Based on my retinal imaging and function tests, does my presentation look more like retinitis pigmentosa, cone-rod dystrophy, or mainly macular disease?
• How often should my central vision and retinal structure be monitored?
• Are there low-vision or rehabilitation services you would recommend starting now?
• What does my result mean for my siblings and children, and would genetic counseling be helpful for them?
• Are there registries or natural-history studies for CERKL-related disease that I could consider?

If a CERKL result comes from a screening panel, confirming it with a specialist and a genetic counselor can help clarify what it means for you. A retinal specialist can document your baseline vision and retinal structure, which is valuable for tracking change over time. You can explore whether any studies may be relevant to you using RP Hope's Clinical Trials Finder.